Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
复制标题
DOI：
10.1086/378416
复制
发表时间：
2003-10-01
影响因子：
6.4
通讯作者：
Brennan, CA
中科院分区：
文献类型：
--
作者：
DeJesus, E;Wald, A;Brennan, CA
为确定伐昔洛韦（500 mg，每日两次）抑制人类免疫缺陷病毒（HIV）感染受试者复发性生殖器单纯疱疹病毒感染的有效性和安全性，进行了一项随机、双盲、安慰剂对照、多中心国际试验。共有293名接受抗逆转录病毒治疗的HIV血清阳性受试者入组。万乃洛韦组6个月时生殖器疱疹未复发的受试者比例为65%，安慰剂组为26%（相对危险度为2.5，95%可信区间为1.8-3.5）。安慰剂组生殖器疱疹首次复发的时间（中位数，59天）明显短于伐昔洛韦组（中位数，>180天）。伐昔洛韦耐受性良好;当考虑治疗持续时间时，2个治疗组的不良事件发生率相似。未发生血栓性微血管病。万乃洛韦对HIV感染者生殖器疱疹复发性感染的抑制是安全有效的。
To determine the efficacy and safety of valacyclovir (500 mg twice daily) for the suppression of recurrent genital herpes simplex virus infections in human immunodeficiency virus (HIV)-infected subjects, a randomized, double-blind, placebo-controlled, multicenter international trial was conducted. A total of 293 HIV-seropositive subjects receiving antiretroviral therapy were enrolled. The proportion of subjects who did not have a recurrence of genital herpes at 6 months was 65% among valacyclovir recipients versus 26% among placebo recipients ( relative risk, 2.5; 95% confidence interval, 1.8-3.5). The time to first genital herpes recurrence was significantly shorter in the placebo group ( median, 59 days) than in the valacyclovir group (median, >180 days). Valacyclovir was well tolerated; the incidence of adverse events for the 2 treatment groups was similar when the duration of treatment was considered. There were no episodes of thrombotic microangiopathy. Valacyclovir was safe and effective for the suppression of recurrent genital herpes infection in HIV-infected individuals.